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Abstract
Background—The pro-inflammatory cytokines, tumor necrosis factor (TNF)-α, and interleukin
(IL)-17, have been implicated in the pathogenesis of liver fibrosis. In this study, we investigated
the role of TNFα and IL-17 towards induction of profibrotic factor, periostin.
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Methods—HepG2 cells were cultured and treated with inflammatory cytokines, TNFα and
IL-17. Computational promoter sequence analysis of the periostin promoter was performed to
define the putative binding sites for transcription factors. Transcription factors were analyzed by
Western blot and Chromatin Immunoprecipitation. Periostin and transcription factor expression
analysis was performed by RT-PCR, Western blot, and fluorescence microscopy. Type I collagen
expression from fibroblast cultures was analyzed by Western blot and Sircol soluble collagen
assay.
Results—Activation of HepG2 Cells with TNFα and IL-17 enhanced the expression of periostin
(3.5 and 4.4 fold, respectively p<0.05) compared to untreated cells. However, combined treatment
with both TNFα and IL-17 at similar concentration demonstrated a 13.3 fold increase in periostin
(p<0.01), thus suggesting a synergistic role of these cytokines. Periostin promoter analysis and
specific siRNA knock-down revealed that TNFα induces periostin through cJun, while IL-17
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induced periostin via STAT-3 signaling mechanisms. Treatment of the supernatant from the
cytokine activated HepG2 cells on fibroblast cultures induced enhanced expression of type I
collagen (>9.1 fold, p<0.01), indicative of a direct fibrogenic effect of TNFα and IL-17.
Conclusion—TNFα and IL-17 induced fibrogenesis through cJun and STAT-3 mediated
expression of profibrotic biomarker, periostin. Therefore, periostin might serve as a novel
biomarker in early diagnosis of liver fibrosis.
Keywords
Fibrosis; Periostin; Inflammation; Tumor Necrosis Factor; Interleukin; transcription factors

Introduction
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Chronic liver disease is one of the top fifteen leading causes of death in the United States
(Murphy et al., 2010). Most common causes of chronic liver disease include: viral hepatitis,
alcoholism, metabolic and autoimmune diseases (Schuppan and Afdhal, 2008). The
progression from healthy liver tissue to cirrhosis is mediated by a chronic inflammatory
reaction eventually leading to the excess deposition of extracellular matrix proteins
(Friedman, 2008). The inflammatory reaction is considered to be the key predictor of disease
progression (Argo et al., 2009; Asselah et al., 2005). The accumulation of ECM proteins
distorts the hepatic architecture by forming a fibrous scar, and the subsequent development
of nodules of regenerating hepatocytes leading to cirrhosis. Hepatic fibrosis is generally
considered to be an irreversible process manifested by a collapse in the hepatic parenchyma
and its substitution with a collagen-rich tissue (Bataller and Brenner, 2005). Animal models
and cell culture studies on liver fibrogenesis led to the identification of key fibrotic
biomarkers (Hayashi and Sakai, 2011). Research and understanding in the pathogenesis of
liver fibrosis could aid the development of novel therapeutic strategies to prevent and
possibly reverse the disease progression.
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Inflammation is an important starting event of liver fibrosis (Czaja, 2014). Inflammatory
cytokine levels are elevated independently of the etiology of the underlying liver disease
(Tilg et al., 2006). Among the pro-inflammatory cytokines, tumor necrosis factor-alpha
(TNFα) is a potent cytokine that exerts pleiotropic inflammatory and immunological
functions by triggering downstream signaling events leading to hepatic fibrosis (Osawa et
al., 2013). Levels of circulating TNFα are increased in patients with liver fibrosis and are
associated with poor prognosis (Odeh et al., 2005). Further in an experimental cholestasis
induced by bile duct ligation TNFα and IL-6 were elevated indicating the pathogenic nature
of these cytokines (Gabele et al., 2009; Odeh, 2007). Hepatic macrophages in chronic liver
inflammation exhibit high levels of TNFα expression (Zimmermann et al., 2012). TNFα has
also been demonstrated to induce fibrosis in other models. In a model of pulmonary fibrosis,
TNFα receptor knockout mice were protected from the development of fibroproliferative
lesions (MacEwan, 2002). Also, hepatic injury following administration of the hepatotoxin
carbon tetrachloride was inhibited in TNFα knockout mice (Sudo et al., 2005). Along with
TNFα alpha another inflammatory cytokine IL-17 has been implicated in the liver fibrosis
(Tang et al., 2011). IL-17A plays a critical role in neutrophil recruitment, angiogenesis,
inflammation, and autoimmune disease that has been previously described extensively
Mol Immunol. Author manuscript; available in PMC 2016 March 01.
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(Miyamoto et al., 2003), including in pulmonary and cardiac fibrosis via IL-17 receptor
mediated signaling (Gasse et al., 2011; Zhu et al., 2011). Although these cytokines induce
fibrotic events, to date, very limited data is available on fibrotic biomarkers with therapeutic
value.
Periostin is a 90-kD secretory protein, playing an important role in the development of
bones, teeth and tumor progression (Hamilton, 2008; Ruan et al., 2009). Recent evidence
suggests that expression of periostin is involved in various pathophysiological statuses of
fibrosis, including the healing process in myocardial infarction, pulmonary fibrosis and bone
marrow fibrosis (Oka et al., 2007; Oku et al., 2008). Studies from lung models indicate that
periostin contributes to the formation of fibrosis in response to inflammatory cytokines
(Sidhu et al., 2010). In this report, we demonstrate that TNF and IL-17 exert a synergistic
effect on HepG2 cells through two different signaling pathways leading to enhanced
periostin expression and eventual induction of Type I collagen expression, a potential
pathogenic mechanism in liver fibrosis.

Materials and Methods
NIH-PA Author Manuscript

Cell culture
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Total protein extraction and Western blot analysis

HepG2 cells were obtained from the American Type Culture Collection (HB-8065, ATCC,
Manassas, VA) and cultured in cell basal essential media (30–2003, ATCC, Manassas, VA)
along with the media supplements as recommended by the manufacturers (Sarma et al.,
2014). Normal neonatal human fibroblasts (PCS-201-010™, ATCC, Manassas, VA) and
normal adult human dermal fibroblasts (PCS-201-012, ATCC, Manassas, VA) were also
obtained from the same vendor and cultured as per the manufacture’s protocol. Cell lines
were frozen in liquid vapor nitrogen at −130°C until use. Upon thawing, cells were
maintained in 5% CO2 incubator in sterile essential media at 37°C. Cells were then
stimulated with varying concentration (0–1000 ng/mL) of TNF or IL-17 or both (Life
Technologies, Grand Island, NY) for 48–72 hours. Specific siRNA (Santa Cruz Biotech,
Dallas, TX) mediated gene knock-down of STAT-3 (sc-29493) and cJun (sc-29223). The
knockdown efficiency was measured by qPCR. All experiments were performed in
triplicates.

Total proteins were extracted from cells with lysis buffer (50mM HEPES [pH 7.6], 150mM
NaCl, 1% Triton X-100, 30mM Na4P2O7, 10% glycerol, 1mM benzamidine, 1mM DTT,
10µg of leupeptin/ml, 1mM phenylmethylsulfonyl fluoride 50mM NaF, 1mM sodium
orthovandate, 10mM sodium pyrophosphate decahydrate, 10mM β-glycerophosphate
(Sigma Aldrich, MO) (Tiriveedhi et al., 2012a). After cell lysis, the supernatant was
collected and run at 15,000 × g for 15min at 4°C.
Nuclear Protein extraction
Nuclear proteins were extracted from HepG2 cells with initial resuspension in Buffer 1 with
protease and phosphatase inhibitors (100mM HEPES, 5mM KCl, 0.5mM MgCl2, 0.1mM
EDTA, 1mM DTT, 10µg/mL of aprotinin A, 10µg/mL of leupeptin, 1 mM PMSF, 50mM
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NaF, 1mM sodium orthovandate, 10mM sodium pyrophosphate decahydrate, 10mM βglycerophosphate) and later resuspended in equivolume mix of Buffer 1 and Buffer 2
(12.25mL of Buffer 1 + 250µL NP-40) to extract the cytosolic proteins from the supernatant.
The resultant pellet of cell lysates were centrifuged at 12,000 × g for 1min at 4°C, and the
remaining nuclear material were solubilized in Buffer 3 (250mM HEPES, 350mM NaCl,
10% sucrose, 1mM EDTA, 1mM DTT, 10µg/mL of aprotinin A, 10µg mL of leupeptin,
1mM PMSF) (Tiriveedhi et al., 2012a).
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Protein concentration was determined with a Bradford assay kit from Bio-Rad
(Philadelphia.PA). Total proteins were separated on a 4–12% sodium dodecyl sulfatepolyacrylamide gradient gel and electrophoretically transferred onto a nitrocellulose
membrane. The membranes were blocked overnight at 4°C in Tris-buffered saline with
0.05% Tween 20 (5% nonfat milk in 10mM Tris-HCl-100mM NaCl-0. 1% Tween 20, pH
7.4). The membranes were incubated first with Abs specific for total and phosphorylated
forms at room temperature with primary Abs diluted 1 in 1,000 in blocking buffer for 2hrs,
and then with a horseradish peroxide-conjugated secondary IgG mAb diluted 1 in 5,000 for
1hr. All primary and secondary Abs were obtained from Santa Cruz Biotech (Dallas, TX).
The following specific primary antibodies to periostin (sc-67233), STAT-3 (sc-482), c-Jun
(sc-1694), and Actin (sc-10731) were utilized. Phosphorylated forms were probed with
phospho-specific primary antibodies: Ser-727-p-STAT-3 (sc-21876) Thr-183/Tyr185/c-Jun
(sc-293136), respectively. The membrane was developed using the chemiluminescence kit
(Millipore) and analyzed on using Bio-Rad Universal Hood II (Hercules, CA).
Morphometric analysis was done using the software provided by the company.
mRNA expression analysis
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Expression profiles of intracellular signalling genes in the HepG2 cells were analyzed using
the FAM-labeled RT-PCR primers for Periostin (Hs01566748_m1), c-Jun
(Hs99999141_s1), Stat-3 (Hs01051722_s1), GADPH (Hs402869), Actin (Hs4333762T),
and Type I collagen (Hs01103892_g1) obtained from Applied Biosystems/Life
Technologies (Grand Island, NY) as per the manufacturer’s recommendation. Briefly, total
RNA was extracted from 106 cells using TRIzol reagent (Sigma–Aldrich, St Louis, MO)
(Tiriveedhi et al., 2012b). RNA samples were quantified by absorbance at 260nm. The RNA
was reverse-transcribed and RT-PCR (real time PCR) was performed in a final reaction
volume of 50µL using iCycler 480 Probes Master (Roche Diagnostics, Indianapolis, IN).
Each sample was analyzed in triplicate. Cycling conditions consisted of an initial
denaturation of 95°C for 15min, followed by 40 cycles of 95°C for 30s, followed by 61°C
for 1min.
Immunofluorescence microscopy
For staining of periostin, 50,000 HEPG2 cells were grown on coverslips in 24-well plates
(Sarma et al., 2014). Cells were fixed with 4% paraformaldehyde and permeabilized with
0.1% Triton X-100. 2% normal goat serum in DPBS (Dulbecco’s phosphate-buffered saline,
Life Technologies, Grand Island, NY) with 1% BSA, 0.1% Tween 20 was used for blocking
and washing. The specific primary antibodies and corresponding PE-conjugated
immunofluorescence antibodies (eBioscience, SanDiego, CA) were used. The images were
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captured using an Eclipse 80i fluorescence microscope (Nikon, NY) and processed using
Metamorph version 6.3r2 software (Molecular Devices, CA).
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Plasmids and siRNA constructs
For the reporter constructs, the periostin promoter regions (−4000 to +50 bp) were amplified
from human genomic DNA (Zyagen, CA) by PCR using iProof High-Fidelity DNA
Polymerase (Bio-Rad, CA). The PCR products were subcloned into the pGL4.11 vector
(Promega, WI) upstream of a luciferase gene using the KpnI/EcoRV restriction sites.
Computational analysis to identify promoter-bound transcription factors was done using the
Transcription Element Search System (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess).
Luciferase reporter assay
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HepG2 cells (1 × 105) were transfected in 24-well plates with 1 µg pGL4.11 luciferase
reporter vector driven by the periostin promoters, or with 2 µg control vector (Sarma et al.,
2014). For transfection of HEPG2 cells (ATCC), 0.2×105 cells were seeded into each well
of a 24 well plate and grown for 24–48 hours. On the day of transfection, medium was
changed and 500 ng of DNA was transfected using Lipofectamine™ LTX and Plus Reagent
(Invitrogen, NY). For siRNA delivery 0.1×105 cells were grown in each well of a 24 well
plate for 24–48 hours in antibiotic free medium and 80 pico moles of siRNA were
transfected using Lipofectamine™ RNAiMAX (Invitrogen, NY). Cells were harvested 48
hours post transfection and efficiency was measured by qPCR, immunostaining and western
blot.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried out with ChIP-IT Express (Active
Motif, CA) according to the manufacturer's instructions (Sarma et al., 2014). One
microgram of Abs for control IgG, c-Jun, or STAT3, was used to immunoprecipitate DNAprotein complexes. CCL2 promoter regions were amplified using PCR and resolved on 2%
agarose gels. The images were acquired with the Chemidoc XRS System (Bio-Rad).
Co-immunoprecipitation
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For cJun and STAT-3 immunoprecipitation HepG2 cells were washed with cold DPBS, and
lysed for 30 min on ice with 0.5 mL of lysis buffer (10 mM Tris-HCl pH 7.5, 0.4 M NaCl,
1% NP-40, 0.4% Triton X-100, 0.2% sodium deoxycholate, 1 mM EDTA, protease
inhibitors (Roche), 1 mM PMSF). To the lysis buffer 0.5 mL of dilution buffer (10 mM TrisHCl pH 7.5, 1 mM EDTA, protease inhibitors, 1 mM PMSF) was added, followed by
centrifugation at 17,000 × g for 30 min. The supernatant was transferred and 1 µg normal
mouse IgG or mouse anti-cJun or mouse anti-STAT-3 were added. After overnight
incubation at 4°C, 30 µL Protein G beads were added to lysates and incubated for 2 hours.
Beads were washed with 700 µL of wash buffer (10 mM Tris-HCl pH 7.5, 0.2 M NaCl,
0.5% NP-40, 0.2% Triton X-100, 0.1% sodium deoxycholate, 1 mM EDTA, 1× protease
inhibitors, 1 mM PMSF) five times, 3 min each time followed by centrifugation at 1,800 × g
for 3 min at 4°C. Beads were then washed with cold DPBS and bound proteins were eluted
by boiling with 30 µL of 2× SDS buffer (0.1 M Tris-HCl pH 6.8, 3.5% SDS, 10% Glycerol,
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2 mM DTT, 0.004% bromophenol blue) for 10 min. Proteins were subjected to SDS-PAGE
(4–12% gel) and immunoblotting. cJun or STAT-3 were detected with a rabbit anti-cJun or a
rabbit anti-STAT-3 respectively.
Enzyme-linked immunoassay (ELISA)
The secretory extracellular periostin in the cell supernatant was quantitatied by ELISA.
Periostin ELISA was performed as per the manufacturer’s protocol (BioVision Inc, Milpitas,
CA). Given the limitation of the detection, the supernatant was diluted 1:1000 and quantified
with a standard curve using the manufacturer provided standards. Detection at 450 nm was
performed using EMax Plus spectrophotometer and data analysis was carried out using
software provided by the manufacturer (Molecular Devices, Sunyvale, CA).
Collagen Assay
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Total soluble collagen content in cell lysates was measured using Sircol soluble collagen
assays (CRLS1000) as described in the manufacturer’s protocol (Accurate Chemical ad
Scientific Corp, Westbury, NY) (Sidhu et al., 2010). Cells were prepared by washing with
cold PBS solution, treated with 0.5 M acetic acid, freeze/thawed, and digested with pepsin
overnight at 4 °C. Samples were centrifuged to remove insoluble debris then incubated with
Sircol dye reagent for 30 min at room temperature on a shaker. Samples then spun to pack
the insoluble collagen–dye complex and excess liquid decanted off. One milliliter of alkali
reagent was then added and mixed to dissolve bound dye and samples were assayed at 540
nm on a EMax Plus spectrophotometer and data analysis was carried out using software
provided by the manufacturer (Molecular Devices, Sunyvale, CA). Collagen standards were
used as controls.
Statistical analysis
Data are expressed as mean ± SEM from four independent studies. Statistical differences
between means were analyzed using a paired or unpaired Student’s t test. A p-value of less
than 0.05 was considered significant. All data analysis was obtained using Origin 7 software
(Origin Labs, Northampton, MA) or GraphPad5 (Graph Pad Software, LaJolla, CA).

RESULTS
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Increased expression of periostin upon activation of Hep-G2 cells with TNFα and IL-17
Studies in the literature have reported the role of TNFα and IL-17 in hepatic fibrosis. As
periostin is a key pro-fibrotic signal molecule and biomarker, we performed experiments to
determine the role of these pro-inflammatory cytokines in the expression of the periostin
protein. We have treated the HepG2 cells, a perpetual hepato carcinoma cell line, with 50
ng/mL of either TNFα, or IL-17, or a combination of both cytokines. As shown in figure
1A, intracellular immunohistochemical staining of HepG2 cells for periostin demonstrated
an increased expression of the protein following co-treatment with both TNFα and IL-17.
This is further verified by western blot analysis (figure 1B). Quantitative mRNA analysis of
the periostin (figure 1C) demonstrated that under basal conditions there was minimal to no
expression of periostin (1.0 ± 0.2 fold), but following treatment with either TNFα or IL-17
alone there was a significant elevation of periostin mRNA expression (3.5 ± 1.1 fold and 4.4
Mol Immunol. Author manuscript; available in PMC 2016 March 01.
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± 0.9 fold, respectively p<0.05). However, a co-treatment of both TNFα and IL-17
demonstrated a 13.3±3.8 fold increased expression (p<0.05) over the basal conditions.
Importantly, treatment with anti-inflammatory cytokine IL-10 demonstrated no enhanced
expression of periostin (0.5 ± 0.3 fold, p=0.83) over basal conditions. Further dosedependent studies were performed using various concentrations (1 to 1000 ng/mL) of TNFα
and Il-17. As shown in figure 1D and E, individual treatment with these pro-inflammatory
cytokines only induced a maximum of 3.5 fold enhanced expression even at 1000 ng/mL
concentration, as against 13.3 fold expression with co-treatment (50 ng/mL of TNFα+50
ng/mL of IL-17). Thus we demonstrate that co-treatment with TNFα and IL-17 caused
approximately a 4 fold increase above the individual cytokine treatment with either TNFα or
IL-17. It is important to note in dose response curves (figure 1D ad E) that individual
treatment with 50 ng/mL TNFα or IL-17 lead to almost (>90%) saturation kinetics for that
specific cytokine. These data indicate that TNFα and IL-17 exert a synergistic effect.
Furthermore, as the synergistic effect was shown to be higher than the individual saturation
effect, this strongly suggests a possibility of two different pro-fibrotic signaling mechanisms
induced by these two cytokines.
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Specific Modulation of periostin expression by cJun and STAT3
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Based on our previous studies (figure 1) we performed experiments to determine the
transcription factors to specifically delineate the pro-fibrotic signaling events mediated by
TNFα and IL-17. Towards this, we have initially analyzed various transcription factors by
quantitative RT-PCR and found that cJun and STAT-3 demonstrated significantly enhanced
expression. The other transcription factors which we tested and did not induce a significant
change under our current experimental conditions were AP-1, p38, STAT-1, STAT-2,
STAT-5, Akt, mTOR. Western blot (and phosphoblot) studies (figure 2A) following
treatment with 50 ng/mL of TNFα on Hep G2 cells for 30 minutes demonstrated is an
enhanced expression and phosphorylation of cJun while similar dose and conditions with
IL-17 induced an enhanced expression and phosphorylation of STAT-3. However, cotreatment with TNF and IL-17 demonstrated expression and phosphorylation of both cJun
and STAT-3. Quantitative analysis by qRT-PCR demonstrated that there was a 4.4 fold
upregulation of total cJun (figure 2B) following treatment with TNFα, which did not
increase further upon co-treatment with both TNFα and IL-17. Similarly, there was a 3.7
fold upregulation in total STAT-3 (figure 2C) following treatment with IL-17, which did not
increase further change upon co-treatment with both TNFα and IL-17. These data support
our previous assertion that TNFα and IL-17 potentially induce periostin expression through
two different signaling factors.
To confirm that TNFα and IL-17 induce separate pro-fibrotic signaling we performed
siRNA knockdown experiments specific for cJun and STAT-3. As shown in figure 2D,
siRNA knockdown of cJun and STAT-3, individually, following co-treatment with TNFα
and IL-17 demonstrated reduced intracellular staining for periostin. As expected, combined
knock-down of both cJun and STAT-3 completely abolished the periostin expression. This is
further verified by western blot analysis (figure 2E). Quantitative mRNA analysis of the
periostin (figure 2F) demonstrated that cJun knock-down reduced the periostin expression to
5.1± 1.8 fold, while STAT-3 knock-down reduced the periostin expression to 4.6± 1.5 fold
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in previously TNFα and IL-17 co-treated HepG2 cells. As noted earlier in figure 2F, TNFα
and IL-17 co-treatment induced periostin expression (13.3±2.8 fold over basal untreated
levels). Taken together these data confirm that TNFα and IL-17 induce pro-fibrotic
signaling molecule, periostin, in two apparently different signaling mechanisms.
Identification of putative DNA binding transcription factors in the periostin promoter
regions

NIH-PA Author Manuscript

To determine the role of TNFα and IL-17 in periostin expression, the luciferase reporter
construct (figure 3A) containing the −4,000-bp region of the human periostin gene promoter
was transfected into HepG2 cells and treated with TNFα or IL-17 or both, and luciferase
activity was measured. An increase in the periostin reporter activity was observed in TNFα
(6.5 fold, figure 3B) and IL-17 (7.8 fold, figure 3C) treated cells compared to the untreated
cells. Further co-treatment with both TNF and IL-17 demonstrated a 26.3 fold increase
(figure 3D) in Luciferase activity compared to the untreated cells. These data were in line
with our earlier data (figure 1–3) supporting our contention that TNF and IL-17 work
synergistically to ehance periostin expression. Also, this strongly suggests that TNF and
IL-17 activates periostin through modulation of upstream transcription factors cJun and
STAT-3.
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To further specifically identify the putative DNA binding sequences for the transcription
factors in the periostin promoter regions, a computational analysis of −4,000 bp of the
promoter region was performed using TESS. This bioinformatics analysis identified 12
putative DNA binding sites for for c-Jun (TGAGTCA; TGAC/GTCA), and one site for
STAT3 (TTCTTTTGAA) at the bp −2657 position (figure 3A) with putative cJun and
STAT-3 binding sequences close proximity to each other, suggesting that these two
transcription factors may be part of a transcriptional-regulatory complex that mediates
periostin expression. To demonstrate that these transcription factors regulate periostin
expression, HepG2 cells were transfected with the truncated periostin reporter construct and
treated with TNFα, or IL-17 or both (figure 3B–D). As shown in figure 3B, following
treatment with TNFα various truncated regions showed significant decrease (>40% loss of
activity) in reporter activity compared to the non-truncated periostin reporter activity. Of
note, the mutation at −3857 (*TGAGTCA) resulted in highest (>80%) loss of activity. Thus
strongly suggesting that this putative sequence region interacts with the cJun following
TNFα treatment to enhance periostin expression. Similarly, following treatment with IL-17
among various truncated regions the mutation at −2657 (*TTCTTTTGAA) resulted in
highest (>80%) loss of activity compared to the non-truncated periostin reporter activity. As
expected, these two mutants demonstrated highest loss of activity following co-treatment
with TNFα and IL-17 (figure 3D), this strongly suggesting a cooperation between the
factors in regulating periostin expression.
To determine whether cJun and STAT3 bind to adjacent DNA binding sites on the periostin
promoter to form a transcriptional-activation DNA-protein complexes, TNFα, IL-17 or both,
treated HepG2 cells were immunoprecipitated with anti-cJun, or anti-STAT3, or control
IgGs. The chromatin immunoprecipitation (ChIP) and PCR using primers specific for
periostin promoter regions (figure 3E, black bars) demonstrated that cJun, and STAT3 bind
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to the periostin promoter (figure 3E). cJun binds strongly to the −4000 to −3000 bp region
and STAT-3 binds to −3000 to −2000 bp region of the PCR amplicon. The DNA binding
pattern of cJun and STAT-3 strongly correlates with the locations of the consensus binding
sites on the periostin promoter determined by Luciferase reporter activity (figure 3B–D).
ChIP with the control IgGs did not enrich periostin promoter regions, demonstrating the
specificity for these transcription factors. No binding was observed in PCRs carried out with
primers specific for the 300 to+50 bp region of the ACTIN (ACT1) promoter that lacks these
binding sites (figure 3E). The protein-protein complexes were immunoprecipitated with anticJun or anti-STAT-3 or isotype control IgGs and western blot analysis was performed to
probe for the other protein (figure 3F, upper panel: probe with c-Jun antibody and protein
complex pulled down with Stat-3 antibody; lower panel probe with Stat-3 antibody and
protein complex pulled down with c-Jun antibody) supported our contention from the
chromatin immunoprecipitation findings that cJun and STAT-3 were complexed together on
the periostin promoter. Taken together, these data clearly demonstrate that the transcription
factors cJun and STAT-3 synergistically interact and are part of a larger transcriptionregulatory complex enhancing the periostin gene expression.
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Type I Collagen-I expression following activation of fibroblasts with periostin supernatant
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Both TNFα and IL-17 have been implicated in collagen deposition in liver fibrosis. Periostin
being a secretory protein should be secreted into the supernatant by the HepG2 cells
following cytokine stimulation. We therefore determined the direct periostin mediated
fibrotic effect of TNF and IL-17 by treating the fibroblasts with supernatants taken from the
HepG2 cells treated with TNFα, or IL-17, or both. The HepG2 cells were first stimulated by
either TNFα, or IL-17, or both for 48 hours, following which the cells were washed and the
fresh media with not stimulating cytokines was added. The supernatant from this replaced
media was obtained after 24 hours and utilized for periostin quantization and fibroblast
stimulation. As shown figure 4A, following treatment of HepG2 cells with TNFα and IL-17
there was increased in the secretion of the periostin into the supernatant (4.3 ± 0.52 µg/mL),
as compared with individual TNFα (1.2 ± 0.26 µg/mL) or IL-17 (1.3 ± 0.31 µg/mL)
stimulation. Normal neonatal human fibroblasts (figure 4B) and normal adult human dermal
fibroblasts (figure 4C) were treated with supernatant for untreated HepG2 cells showed
basal level of type I collagen expression (1.0±0.3 fold). The normal neonatal human
fibroblasts (figure 4D) treated with supernatant from HepG2 cells treated with TNFα
(2.4±0.5 fold, p<0.05) and IL-17 (3.3±0.4 fold, p<0.05) increase in collagen type I
expression. As expected, the fibroblasts treated with supernatant from HepG2 cells cotreated with TNFα and IL-17 (9.1±1.8 fold, p<0.01) increase in collagen type I expression.
Sircol color assay for the soluble collagen expression from normal neonatal human
fibroblasts (figure 4E) demonstrated that treatment of these cells with supernatant from
HepG2 cells induced basal levels of collagen expression (2.7±0.6 µg/mL) while supernatant
from HepG2 cells treated with TNFα (5.2±0.9 µg/mL, p<0.05), IL-17 (5.9±1.1 µg/mL,
p<0.05), and TNFα and IL-17 (10.1±2.3 µg/mL, p<0.01) induced enhanced collagen
expression. Similarly normal human adult dermal fibroblasts (figure 4F) treated with
supernatant from HepG2 cells treated with TNFα (1.7±0.4 fold, p<0.05) and IL-17 (2.1±0.5
fold, p<0.05) increase in collagen type I expression. As expected, the normal human adult
dermal fibroblasts treated with supernatant from HepG2 cells co-treated with TNFα and
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IL-17 (6.1±1.1 fold, p<0.01) increase in collagen type I expression. Sircol color assay for
the soluble collagen expression from normal human adult dermal fibroblasts (figure 4G)
demonstrated that treatment of these cells with supernatant from HepG2 cells induced basal
levels of collagen expression (0.6±0.2 µg/mL) while supernatant from HepG2 cells treated
with TNFα (2.8±0.6 µg/mL, p<0.05), IL-17 (3.9±0.7 µg/mL, p<0.05), and TNFα and IL-17
(7.8±1.9 µg/mL, p<0.01) induced enhanced collagen expression. These findings from two
different fibroblast cell lines confirm that TNFα and IL-17 induce periostin mediated
fibrosis which might potentially explain for the inflammatory cytokine mediated liver
fibrosis in cirrhotic patients.

Discussion
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Liver fibrosis and cirrhosis represent the final common pathway of all chronic liver diseases
(Xu et al., 2012). It results in liver failure and portal hypertension and is associated with an
increased risk of liver cancer (Gines et al., 2004). Advanced hepatic fibrosis is characterized
by an accumulation of type I and III collagens (Iredale, 2007). Further, models of liver
fibrosis, which include cell culture, animal and explanted human tissue, have demonstrated
that live fibrosis is a highly dynamic example of solid organ wound healing (Bataller and
Brenner, 2005). Currently the only effective available treatment for cirrhosis is liver
transplantation (Murray and Carithers, 2005). However, shortages of organs and the
presence of concurrent diseases in the donors limit the availability of this treatment to all
patients (Murray and Carithers, 2005). Clearly, development of novel anti-fibrotic therapies
are needed to improve the morbidity and mortality of these patients (Cohen-Naftaly and
Friedman, 2011). Increased understanding of the pathogenesis of liver fibrosis in past two
decades lead to the identification of the main cellular effectors of liver fibrosis, the key
cytokines regulating the fibrotic process, and the determinants of ECM turnover,
highlighting an array of potential therapeutic approaches that could be developed in the near
future (Cohen-Naftaly and Friedman, 2011).
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Evidence on the role of periostin in liver diseases is limited. To date, the majority of reports
on periostin in liver have ben predominantly from liver tumors and bile duct carcinomas
(Riener et al., 2010). However, periostin has been extensively studied in various
inflammatory lung diseases. Takayama et al (Takayama et al., 2006) using a murine model
for bronchial asthma have demonstrated that periostin plays a key role in alveolar supepithelial fibrosis under stimulation of pro-inflammatory cytokines IL-4 and IL-13. Later
studies by Fahy and colleagues (Woodruff et al., 2007; Woodruff et al., 2009) have
confirmed the upregulation of periostin in asthma patients. The pathological role of periostin
and the precise molecular mechanisms leading to inflammation induced upregulation of
periostin still remain unknown. In line with these published data, our current studies
demonstrate that pro-inflammatory cytokines TNFα and IL-17 work synergistically towards
enhanced expression of periostin (figure 1) in HepG2 cells, thus suggesting a potential role
of periostin in liver inflammatory injury. Furthermore, it of interest to note that, not just
limited to liver, the synergistic effect of TNFα and IL-17 have also been noted in other
inflammatory diseases such as psoriasis leading to altered keratinocyte differentiation
(Chiricozzi et al., 2011).
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Inflammatory cytokines, TNFα and IL-17, have been implicated in several fibrotic and liver
diseases (Osawa et al., 2013; Tang et al., 2011). Therefore, in our current report we studied
the molecular events leading to the upregulation of periostin in liver cells following
stimulation with pro-inflammatory cytokines TNF and IL-17. Murine TNFα receptor knock
out models have demonstrated that TNFα stimulated collagen synthesis, increased
expression of TIMP-1, and decreased activity of MMP-2 (Theiss et al., 2005; Verrecchia et
al., 2002). Similar to TNFα, Meng et al. (Meng et al., 2012), using a murine liver fibrosis
model have demonstrated that hepatic stellate cells activation by IL-17 induces collagen
deposition and fibrosis using a STAT-3 signaling mechanism. In our current studies we
demonstrated that TNFα and IL-17 exert synergistic effect towards enhanced expression of
periostin. TNFα induced expression of periostin through the transcription factor c-Jun, while
IL-17 induced expression through STAT-3 (figure 3). Both these transcription factors act on
the periostin promoter forming a transcription regulator complex, and there by inducing
periostin expression (Figure 4). We have previously demonstrated that STAT-3 plays a
criticial role in IL-6 induced CCL2 expression in hepatitis patients developing cirrhosis and
acute liver failure (Sarma et al., 2014). In line with our current studies, Kluwe et al (Kluwe
et al., 2010) have previously demonstrated that in carbon tetrachloride induced murine liver
fibrosis model, inhibition of c-Jun inhibits the development and progression of hepatic
fibrosis. Further, it is of interest to note that patients with chronic hepatitis C who displayed
decreased fibrosis in response to the angiotensin receptor type 1 blocker losartan showed
decreased cJun expression and phosphorylation (Kluwe et al., 2010). The role of IL-17
mediated collagen deposition in a matrix metaloproteinase (MMP) mediated manner was
also established in other chronic inflammatory diseases such as rheumatoid arthritis (Koshy
et al., 2002). The c-Jun/JNK pathway is known to induce fibrosis in kidney (Ma et al., 2007)
and lung diseases (Tiriveedhi et al., 2012a). Previous studies in our lung transplant models
demonstrated that cJun activation by hypoxia inducble factor (HIF1α) potentially induced
VEGF upegulation with potential fibrotic effect (Tiriveedhi et al., 2012a). Prele et al have
demonstrated that STAT-3 is the key central factor in inducing idiopathic pulmonary
disease, a fibrotic lung disease (Prele et al., 2012). Transcription factor STAT-3 is involved
in JAK/STAT signaling pathway. Mice with STAT-3-deficient hepatocytes exhibit defects
in their ability to induce acute phase response genes such as, serum amyloid protein,
fibrinogen, haptoglobin, serum amyloid A protein, and hemopexin in response to
inflammatory cytokine activation (Alonzi et al., 2001). This body of evidence along with our
current studies strongly suggest the potential application of periostin, c-Jun, and STAT-3 as
potential fibrotic biomarkers with potential anti-fibrotic drug target application. Our current
study was limited with the high concentration of cytokines needed for cell culture studies.
Therefore further studies in animal models and human diseases studies are warranted.

Conclusion
Currently, liver biopsy is the only clinical diagnostic method for diagnosis of liver fibrosis
(Bataller and Brenner, 2005). Although this technique has the advantage of staging the liver
fibrosis, characterizing the parenchymal architecture, a number of inherent problems also
limit the accuracy of liver biopsy in determining fibrosis stage (Adams, 2011). It has been
estimated a standard liver biopsy represents 1/50 000th of the liver, and thus sampling error
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is a significant problem (Adams, 2011). The mere invasive nature of this procedure, limits
the use only on patients with high degree of suspicion. A development of less-invasive
fibrotic biomarker detection strategy would be a futuristic diagnostic strategy. Using indirect
liver enzyme markers such as aminotransferases would not be a good marker for fibrotic
activity (Rosenberg et al., 2004). Currently, inflammatory cytokine levels (TNFα, TGFβ etc)
are the employed as anecdotal markers of fibrotic activity (Rosenberg et al., 2004). Periostin
being a secretory protein could be a potential biomarker for liver fibrosis. Further clinical
research to ascertain the sensitivity and specificity of periostin as a novel fibrotic biomarker
could be immensely beneficial in the early diagnosis of patients potentially developing liver
fibrosis.
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Tumor Necrosis Factor
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Interleukin
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Liver hepatocellular carcinoma cell line
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ethylenediaminetetraacetic acid
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•

TNFα, and IL-17 have been implicated in the pathogenesis of liver fibrosis.

•

TNFα through induction of cJun and IL-17 through induction of STAT-3 exert a
synergistic effect on the expression of periostin.

•

Periostin induces collagen deposition.

•

Therefore, periostin could be used a novel biomarker for early liver fibrosis.
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Figure 1.

Increased periostin expression in HepG2 cells following stimulation with TNFα and IL-17.
(A) Immunostaining of HepG2 cells with periostin following treatment with with TNFα (50
ng/mL), or IL-17 (50 ng/mL) or both (TNFα-50 ng/mL and IL-17–50 ng/mL). Periostin
probed with rabbit anti-human primary antibody at 1: 100 and later probed by PEconjugated oat anti-rabbit secondary antibody at 1:200. (B) Western blot analysis of
perisotin expression in the hepG2 cells. The cell lystate probed by appropriate primary and
secondary antibody. The representative periostin protein band at 93 kDa is shown. Anti-
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inflammatory cytokine IL-10 was utilized as negative control at two concentrations 50 and
100 (2×) ng/mL. (C) Periostin mRNA expression analyzed by quantitative RT-PCR.
Quantitation done by ΔΔcT method normalized for GADPH expression. (D and E) Dose
dependent changes in the mRNA expression of periostin in the HepG2 cells following
stimulation by TNFα (0–1000 ng/mL) (D) and IL-17 TNFα (0–1000 ng/mL) (E). All data
represented as mean values ± SEM from four independent experiments.
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Figure 2.

Induction of transcription factors cJun and STAT-3 in HepG2 cells following stimulation
with TNFα and IL-17, respectively. (A) Western blot analysis was performed to determine
the protein level expression of cJun (43 kDa), p-cJun (43 kDa), STAT-3 (86 kDa), pSTAT-3 (86 kDa), STAT-6 (116 kDa), and Actin (43 kDa) for both total and active
phosphorylated forms analyzed after 30 min stimulation with TNFα, or IL-17 or both; (B
and C) quantitative mRNA expression of cJun (B), and STAT-3 (C) by qRT-PCR analyzed
after 30 min stimulation with TNFα, or IL-17 or both. Quantitation done by ΔΔcT method
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normalized for GADPH expression. (D) Immunostaining of HepG2 cells with periostin
following treatment with with both TNFα and IL-17, and specific siRNA knock down of
cJun and STAT-3. (E) Western blot analysis of perisotin expression in the hepG2 cells
following stimulation with TNFα and IL-17 along with cJun and STAT-3 knock-down by
specific siRNA. Scramble siRNA usd as negative control. (F) Periostin mRNA expression
analyzed by quantitative RT-PCR in the hepG2 cells following stimulation with TNFα and
IL-17 along with cJun and STAT-3 knock-down by specific siRNA. Quantitation done by
ΔΔcT method normalized for GADPH expression. All data represented as mean values ±
SEM from four independent experiments.
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Figure 3.

cJun and STAT-3 bind to periostin promoter and activate transcription. (A) Schematic of the
periostin gene promoter cloned in the luciferase reporter. Computational analysis of −4000
bp upstream of the open reading frame using the Transcription Element Search System
(TESS). The lines in the schematic at −3857 and −2657 represent the predicted consensus
binding sites in the DNA for transcription factors cJun and STAT-3, respectively. (B–D)
HepG2 were transfected with luciferase reporters driven by deletion constructs of periostin
promoter (−4000 to+50 bp; −4000 to −1000 bp; −4000 to −2000 bp; −4000 to −3000 bp;
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−2000 to +50 bp; mutation *Δ2657 bp/−4000 to +50 bp; and mutation *Δ3857 bp/−4000 to
+50 bp) construct and stimulated with TNFα (B), or, IL-17 (C), or both (D). Firefly
luciferase activity was measured 48 hours after transfection and normalized to a Renilla
luciferase internal control. The numbers represent fold-change over the control vector
(average of three independent experiments); error bars represent S.D. (E) Periostin promoter
showing binding sites for cJun and STAT-3. The black horizontal bars represent regions
amplified by the PCR primers. Chromatin was immunoprecipitated with anti-cJun or antiSTAT-3 or isotype control IgG from HepG2 cells following stimulation with both TNFα
and IL-17. Segments of the periostin promoter were amplified by PCR. The first three lanes
show immunoprecipitated with chromatin (ChIP) and the fourth lane show input chromatin
(Input). ACTIN promoter amplification is shown as the negative control (F) CoImmunoprecitation of protein-complex extracted by anti-STAT-3 and anti-cJun and Western
blot analysis to probe with the opposite antibody (upper panel: probe with c-Jun antibody
and protein complex pulled down with Stat-3 antibody; lower panel probe with Stat-3
antibody and protein complex pulled down with c-Jun antibody).
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Induction of Collagen expression following activation of fibroblasts with periostin rich
supernatant. (A) Quantitative ELISA analysis of the periostin secreted into the supernatant
by HepG2 cells following stimulation with TNFα, or IL-17, or both. (B) Western blot
analysis of the Type-I Collagen expressed by the normal neonatal human fibroblasts
following treatment with supernatant from HepG2 cells stimulated with TNFα, or IL-17 or
both. (C) Western blot analysis of the Type-I Collagen expressed by the normal adult human
dermal fibroblasts following treatment with supernatant from HepG2 cells stimulated with
TNFα, or IL-17 or both. (D) Densitometric analysis to determine quantitative expression of
Collagen-I in normal neonatal human fibroblasts (under various conditions mentioned in B).
(E) Sircol assay to demonstrate the expression of soluble collagen by fibroblasts in normal
neonatal human fibroblasts (under various conditions mentioned in B). (F) Densitometric
analysis to determine quantitative expression of Collagen-I in normal adult human dermal
fibroblasts (under various conditions mentioned in C). (G) Sircol assay to demonstrate the
expression of soluble collagen by fibroblasts in normal adult human dermal fibroblasts
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(under various conditions mentioned in C). All data represented as mean values ± SEM from
four independent experiments.
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